title: Liver resection in multimodal concepts improves survival of metastatic melanoma: a single-centre case-matched control study.
abstract: OBJECTIVE
  The aim of the present study was to define prognostic factors and to evaluate liver resection as an additive tool in metastatic melanoma.
  
  
  METHODS
  In a case-control study, 32 patients with hepatic melanoma metastasis were analyzed between 1998-2012. Sixteen patients who underwent liver resection (6 patients with multimodal therapy) were matched to 16 patients scheduled for non-surgical approaches. Univariate and multivariate analyses were performed.
  
  
  RESULTS
  Following primary resection and liver resection, respectively, survival was better for patients who underwent surgery in addition to multimodal therapy with 219 and 28 months, when compared to patients scheduled for non-surgical approaches with 64 (p=0.04) and 8 months (p=0.6). Following primary resection, primary tumor site, metastatic time <70 months, combination of multimodal therapy and surgery were of prognostic value (p<0.05).
  
  
  CONCLUSIONS
  Liver resection should be considered a suitable additive tool in multimodal therapy of resectable metastatic melanoma.
authors.affiliation: Department of Visceral, Transplant, Vascular and Thoracic Surgery, University Hospital of Leipzig, Leipzig, Germany.
authors.forename: Hans Michael
authors.initials: HM
authors.lastname: Hau
authors.affiliation: Department of Visceral, Transplant, Vascular and Thoracic Surgery, University Hospital of Leipzig, Leipzig, Germany hansmichael.hau@medizin.uni-leipzig.de.
authors.forename: Hans-Michael
authors.initials: HM
authors.lastname: Tautenhahn
authors.affiliation: Department of Visceral, Transplant, Vascular and Thoracic Surgery, University Hospital of Leipzig, Leipzig, Germany Department of General, Visceral, Transplantation, Vascular and Thorax Surgery, Campus Großhadern, University Hospital in Munich, Munich, Germany.
authors.forename: Markus Bo
authors.initials: MB
authors.lastname: Schoenberg
authors.affiliation: Department of Visceral, Transplant, Vascular and Thoracic Surgery, University Hospital of Leipzig, Leipzig, Germany.
authors.forename: Georgi
authors.initials: G
authors.lastname: Atanasov
authors.affiliation: Department of Visceral, Transplant, Vascular and Thoracic Surgery, University Hospital of Leipzig, Leipzig, Germany.
authors.forename: Georg
authors.initials: G
authors.lastname: Wiltberger
authors.affiliation: Department of Visceral, Transplant, Vascular and Thoracic Surgery, University Hospital of Leipzig, Leipzig, Germany.
authors.forename: Mehmet Haluk
authors.initials: MH
authors.lastname: Morgül
authors.affiliation: Department of Visceral, Transplant, Vascular and Thoracic Surgery, University Hospital of Leipzig, Leipzig, Germany.
authors.forename: Dirk
authors.initials: D
authors.lastname: Uhlmann
authors.affiliation: Department of Dermatology, Venerology and Allergology, University Hospital of Leipzig, Leipzig, Germany.
authors.forename: Anna Theresa
authors.initials: AT
authors.lastname: Seitz
authors.affiliation: Department of Dermatology, Venerology and Allergology, University Hospital of Leipzig, Leipzig, Germany.
authors.forename: Jan C
authors.initials: JC
authors.lastname: Simon
authors.affiliation: Department of Visceral, Transplant, Vascular and Thoracic Surgery, University Hospital of Leipzig, Leipzig, Germany Translational Centre for Regenerative Medicine, University of Leipzig, Leipzig, Germany.
authors.forename: Moritz
authors.initials: M
authors.lastname: Schmelzle
authors.affiliation: Department of Visceral, Transplant, Vascular and Thoracic Surgery, University Hospital of Leipzig, Leipzig, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Bartels
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016022:Case-Control Studies; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006498:Hepatectomy / Q000401:mortality*; D006801:Humans; D007167:Immunotherapy; D007372:Interferons / Q000008:administration & dosage; D007376:Interleukin-2 / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000401:mortality* / Q000556:secondary / Q000601:surgery / Q000628:therapy; D008297:Male; D008545:Melanoma / Q000401:mortality* / Q000473:pathology / Q000601:surgery / Q000628:therapy; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000401:mortality* / Q000473:pathology / Q000601:surgery / Q000628:therapy; D015996:Survival Rate
chemical_list: D007376:Interleukin-2; D003606:Dacarbazine; D007372:Interferons; D002945:Cisplatin
keywords: Melanoma; case-control study; hepatic metastasis; liver resection; multimodal therapy; survival